Commemorating 50 Years of the 1976 Copyright Act, Stanford Law School

The Copyright Act at 50: Evolution and Impact

Shira Perlmutter

Copyright Act took a long time, with input from lots of
interest groups and attention to detail—hundreds of contending and overlapping
interests were involved. Hard to imagine this process today. Desire to avoid
need for constant amendment/future-proofing. But did they do enough? Didn’t
create a general right to exploit the work publicly, which would have obviated
the need for continued parsing the scope of each right, like public
performance.

Some changes over time, most prominently the DMCA. More than
codifying common law principles; tech-specific obligations. Less durable as
business models evolved; might have unexpected consequences in Cox.
[Hunh? Cox is not a DMCA case.] 1201: some provisions are highly detailed and
technical, and outmoded. But the rulemaking process is flexible and fair-use
based and has produced new exceptions. Allows © owners to rely more securely on
TPMs, enabling the celestial jukebox. Fair use has also played a critical role
as a flexible judicial tool. The bones are solid, even with AI.

Q: registration requirement is tough on creators. Can’t get
protection [statutory damages] before infringement.

A: You can register—the issue is remedies.

Chris Sprigman: why do you think that it was ill-considered
to add to fair use that unpublished status isn’t dispositive?

A: b/c courts had already walked back their overreading of
unpublished status. Worried about accretion of more specific language in a
statute that’s supposed to deal with rapid change. [Seems like a levels of
generality issue; unpublished seems general enough to be robust.]

Sprigman: it’s always good when Congress talks back to the
Supreme Court.

Laura Heymann: say more about moral rights?

A: A patchwork in the US; would love to see Dastar
reversed and some additional protections provided.

Q: how to design AI training licensing framework?

A: Doesn’t have proposal but thinks it would be possible;
easier in areas w/high value works. Small low value works w/authors who aren’t
organized are harder. At some point there may be a statutory solution building
on experience in the private sector with making a licensing system work.

Tyler Ochoa: Cox v. Sony?

A: Personal views! Shocked at how short the decision was and
how little thought there seemed to be about the implications. Threw out decades
of © law quickly w/o analysis. Repercussions well beyond the facts. Congress
clearly intended to continue the separate treatment of © contributory liability
from patent and aiding and abetting liability. [Don’t you know that only
Supreme Court cases count? My line on this: “This is easy and you are all
stupid” is a poor way to think in drafting most Supreme Court decisions.]

Do We Need a New One? William Fisher

Statute has grown by accretion, not revision, and only when
there can be agreement by major stakeholders. Hypothesis: useful to start
fresh. Draft from Oren Bracha, William Fisher, Ruth Okediji, and Talha Syed. A
couple of points: Limit scope of adaptation right. Reproduction
right/substantial similarity is almost overlapping with it, but matters when
there’s no reproduction. Independent of exclusive rights of © owner, wants to have
rights attached to, at least initially, authors rather than owners—right to
attribution, generously defined, and to integrity, narrowly defined. Shorter
duration. Compulsory licenses not just for music covers but for educational
uses.

Sprigman: Why is remuneration for authors the first
principle? The Court has said that’s a means to an end. Why not “vibrant
creative environment”?

A: order isn’t meant to connote hierarchy, but worth
thinking about. Utilitarianism isn’t the only goal; fair treatment of artists
is also a goal.

Q: like the use of lessons from laws around the world. Was
that a reason to delete statutory damages, which aren’t available in many places
around the world?

A: there are well-known specific defects in the US system of
statutory damages. The substantial range for willful infringement per work
becomes bizarre & punitive. There are workable models that would function more
like liquidated damages in contracts. The functions of augmented damages,
including incentives to bring suit, could be adequately performed by enhanced
damages for abusive positions (doubling) and attorneys’ fees. Fees should be more
likely for small creators and less likely for deep pocketed plaintiffs.

About Face: Deepfakes and the Misuse of Copyright Madhavi
Sunder

Denmark is granting © in a person’s face to combat
deepfakes. Incentives/progress/access aren’t just buzzwords but the raison d’etre
of our law. But roughly a decade ago, things began changing, not just b/c of
AI: using © as a tool to redress noneconomic social harm: safety, protection,
dignity, reputation.

Denmark goes beyond using © to serve non © ends/do an end
run around 230, as past proposals in the US have done (thanks
for the shout-out
) to expanding the scope of © beyond what it should cover.

Denmark’s amendment covers life of the author+50 years and
protects all natural persons against digitally generated images of personal
characteristics. Limitations for caricature, satire, parody, criticism of
power, social criticism, etc. But this would cover foreign nationals as well. Includes
a takedown right. Drafters suggest that the new right is not really copyright
but personality right, and the law should be changed to be officially called
the “Copyright, etc. Act.” [It’s ©, Jim, but not as we know it!] Attribution
and integrity for authors is not the goal; broad dignity harms to individuals,
society, and democracy.

EU is considering whether to adopt a similar proposal. US
may be heading in a similar direction—Jennifer Rothman identifies convergence
between ROP and ©. Digital replica report by Copyright Office suggests new laws
are needed.

Faces and voices aren’t authored in the way © has
traditionally required; we allow soundalikes. However, some people (Balganesh,
Gilden) suggest that © has always had concerns with dignity. Likewise, the
Court allowed photographers to own © in depictions of faces. This tension
raises charges of unfairness, as in Moore v. University of California. Descendants
of enslaved people can’t claim ownership of daguerrotypes of their ancestors;
Prince, who decried ownership of his name and music, becomes the subject of a
photographer’s © claim at the Supreme Court. Surveillance: your face belongs to
us. The issue about face is not whether property, but whose property.

IP and blackface: Jim Crow was a minstrel character—“love
and theft” of black dances and bodies—loved and despised, coveted and expropriated.
Elvis painstakingly listened to recordings of Black artists on repeat so he could
copy them, and Tennessee then called its voice ROP law the ELVIS Act—irony! Digital
replicas are the next frontier. Abba has created a concert featuring digital
replicas of their younger selves; they sang and danced in motion capture suits
with monitors and cameras everywhere. This show will last as long as people
will pay to see it.

Sunder’s about-face: She criticized the goal of efficiency
in © and argued for considering other interests like semiotic democracy. Is
this the same thing? No. © can’t be everything everywhere all at once.
Doctrinal coherence matters. Doctrinal collapse b/t © and privacy has
structural harms including threats to the rule of law. © is too consequential
and long-lasting and easy-to-get to be careless about; statutory damages and
notice and takedown are big deals.

© is about authors, whether you’re a high protectionist or
low protectionist. In an age where we’re all curated online, we should have a low
threshold for protection, but not create mutant copyrights far from the real thing.

Cathy Gellis: Implications for national treatment?

A: will think about it—interested in whether we’re
replicating it for ourselves.

Lemley: is the right alienable in Denmark? © as a regime is
usually about being able to sell rights.

A: all premised on consent.

Quasi-copyright and the Copyright Act, Rebecca Tushnet

My focus here is on 1201 and 1202. My argument is that their
evolution in the courts shows something about the workings of the legal system
and the incentives of both plaintiffs and judges.

As most of you know, 1201 prohibited circumvention of access
controls and trafficking in technology that circumvented rights controls or
access controls, with a variety of statutory exceptions that are essentially
too complicated to be used, and a provision for allowing additional temporary
exceptions after Copyright Office rulemaking, but only for the direct access control
circumvention provisions not for the trafficking provisions, so you have to
both have an exemption and somehow get the technical capacity to use the exemption
which is illegal for someone to give you.

Tony Reese wrote a great article explaining the benefit to
the copyright owner of characterizing a technological protection as an access
control rather than a rights control – no individual circumvention is allowed
in the absence of an exception– thus in every case, copyright owners plead that
a TPM is an access control, and courts have uniformly accepted this
characterization—so this supposed four part scheme of access and rights
controls, direct circumvention and trafficking, quickly became a two part
scheme involving only access controls. Rights controls immediately lapsed into
desuetude.

Because of how broad 1201’s access control provision was it
initially seemed to offer copyright owners broad new rights. This was
especially important for manufacturers of machines that happened to have
software in them—providing compatible products, for example, could be reframed
as violating access controls. However, in two prominent decisions courts—using interpretive
methodologies that would probably not be adopted today—interpreted 1201 to try
to prevent its use to control markets that aren’t really based on the value of
the copyrighted works; the major cases are perhaps tenuously based in the
statutory language but they probably do track what Congress thought it was
doing.

These two decisions, Chamberlain and Lexmark, dampened the
appetite among many non-copyright-reliant manufacturers to use 1201 to try to
control repair and resale. There’s a real case to be made that 1201 has importance
for phones and apps, but it’s no longer a big part of copyright litigation.

In addition, the rulemaking process proved so exhausting
that the Copyright Office decided to streamline it for existing exemptions. And
because the trafficking provisions only cover traffickers, not customers of
traffickers, people with exemptions use circumvention software they got from
elsewhere and we all just generally ignore the issue in the exemption process. I
would suggest that, at least for the time being, we’re no longer in a legal
innovation phase with 1201.

Meanwhile, 1202 litigation has exploded. 1202 covers knowing
removal of copyright management information that facilitates infringement or
provision of false CMI, and although there were always a few cases about it, it
has been discovered in the last decade—as causes of action sometimes are
because lawyers are innovative—and gained new prominence in cases like the AI training
cases. 1202 doesn’t require registration in order to get statutory damages and
so questions about what constitutes removal of CMI or the relevant intent are
actively being litigated. Pam Samuelson and her coauthors have written a good
article about the arguments, but I just want to point out that lawyers have
done exactly what they’re good at: pushing the boundaries of the law in order
to achieve interests for their clients even when the more obvious claim—like copyright
infringement—won’t work for copyright-specific reasons.

Given this increased use, it’s not surprising that we see countervailing
theories attempting to limit the growth of 1202 cases. One court even recently
dismissed a lawsuit brought under 1202(b)(1) against ChatGPT on Article III
standing grounds—under the TransUnion case, 1202 can’t constitutionally
authorize a private cause of action for internal CMI removal that goes no
further—plaintiffs didn’t allege any actual harm beyond the removal of CMI in
the training dataset, so they didn’t have standing to seek damages, and they
didn’t plausibly allege that a substantial amount of their creative expression
would appear in future results, so they didn’t have standing to seek injunctive
relief.

I have some broader thoughts about this incredibly abbreviated
account, based on Carol Rose’s classic article, Crystals and Mud in Property
Law: Fools and scoundrels are the bane of the law because they make it
unpalatable to follow the most natural understanding of a clear rule. Hard
edged rules written into law—like the prohibition on circumventing access
controls—predictably lead scoundrels to abuse their fellow citizens, as in Lexmark
and Chamberlain, and subjects fools to disproportionate liability, especially where
statutory damages are involved. Courts then understandably push back, inventing
equitable limits and turning a clear rule into something more muddy. But muddy
rules are expensive to navigate and create their own set of problems.

In Carol Rose’s story about real property law, legislatures eventually
intervene to create a new and different clear rule designed to solve the problems
created by existing fools and scoundrels under the previous regime. This works
for a while and then the infinite creativity of humans, both good and bad, produces
new fools and new scoundrels.

I think Rose’s story has key lessons for copyright. (1) Future
proofing is something of a myth. It’s worth trying, because immediate obsolescence
when a few facts about the market change is not good—I’m looking at you, vessel
boat hull and mask works protection and 512(b)—but the idea that you can set
and forget a law ignores the fact that lawyers and judges are human beings—at least
for now—and human beings are collectively really good at finding ambiguity or opportunities
for arbitrage.

(2) If we face a situation where we don’t trust that the
legislature will intervene, or can intervene productively, then things get a
lot harder. When that’s combined with a judicial approach to statutes that
focuses on the dictionary meaning of specific words rather than an appreciation
for the structure of the legislation and the context in which the legislature
was operating, scoundrels are likely to prosper and fools are likely to be
abandoned to their fates. I don’t have solutions but I am predicting a long roll
in the mud.

Lots of interesting comments; I think both the legislative
process (actual deliberation) and judicial concepts of the role (neither
entirely free to disregard the statute in favor of the common law/equity nor laser
focused on individual words in isolation from the structure and purpose of the
law as a whole) need change from where they are.

Tony Reese pointed out that the Copyright Office testified in the legislative history that many things were “clear” but didn’t need to be in the statute–should we revise to make those things explicit? I think the issue w/that is the fools/scoundrels problem–one reason you might not write out the exact wording is that you can’t foresee what will happen when clever lawyers get their hands on it directly and treat a principle as a rule. This is a classic content moderation problem! 

from Blogger https://tushnet.blogspot.com/2026/04/commemorating-50-years-of-1976.html

Posted in Uncategorized | Tagged , , , , | Leave a comment

court gives guidance on disclaimer placement, AI alterations in enforcement proceeding

InSinkErator LLC v. Joneca Company LLC, 2025 WL 4631972, No.
8:24-cv-02600-JVS-ADS (C.D. Cal. Nov. 24, 2025)

Previous
discussion of this false advertising case
. In a separate order, the court
deals with other compliance issues than those below. It rejects the claim that
the injunction requires Joneca-controlled search results to display the
disclaimer as part of the result. Consumers will only be able to buy the
product by clicking on the link and therefore will see the disclaimer as long
as the underlying result page complies with the injunction.   

InSinkErator moved to enforce the preliminary injunction and
the court granted the motion in part. The injunction barred “Joneca, its
officers, agents, servants, employees, and attorneys, and all other persons who
are in active concert or participation therewith and who have actual notice of
the injunction” from “[m]aking any false and deceptive horsepower claims
regarding Joneca-made garbage disposal products.” Joneca was further enjoined
from “[a]ssisting, permitting, or causing to be made by any third party any
false and deceptive horsepower claims … including on retailer or wholesaler
websites.” It was required to include the following disclaimer on all online
listings of its products: “Horsepower claimed on package does not indicate
motor output or motor power applied for processing.”

InSinkErator reviewed Joneca’s online product listings and
found that the disclaimer was sometimes included in a tab that customers had to
click into or scroll down to in order to obtain more product information. It
argued that this wasn’t good enough.

Civil contempt requires clear and convincing evidence, that
(1) the party violated a court order, (2) beyond substantial compliance, and
(3) not based on a good faith and reasonable interpretation of the order. Violation
of a court order is shown by the party’s “failure to take all reasonable steps
within the party’s power to comply.”

InSinkErator argued that some of Joneca’s disclaimers weren’t
“clear and conspicuous.” “Instead of appearing at the top of the page or in the
first image of the product, the disclaimer sometimes appears in an expandable
section containing product details near the bottom of the webpage.”

Joneca argued that the disclaimer was placed in the “first
permitted or technologically feasible location given each retailer’s specific
restrictions,” usually located next to an explanation of the product’s
horsepower.

The court indicated that the spirit of its order “was that
any reasonable consumer would come across the horsepower disclaimer before
making a purchase” because horsepower is “one of the top purchasing
considerations for garbage disposals.” “This is made evident by the inclusion
of horsepower in the product title of every online listing shown to the Court.”

The court then provides some guidance that might or might
not be generalizable:

For physical packages, the Court’s
Order required the disclaimer to be bordered in red and affixed to the front of
the package. It would thus be difficult for any consumer to purchase a physical
unit without seeing the disclaimer. Any online disclaimer should be similarly
conspicuous and immediately viewable just like on a sign or product package in
a physical store.

A reasonable consumer may not click
through all of the online product details before making a purchasing decision.
Thus, to be sufficiently conspicuous—analogous to the disclaimer on a physical
package—the online disclaimer must be immediately viewable to the consumer
without additional navigation on the product listing. This means that the
disclaimer must not be located only in a product description lower on the page
or in a separate tab, but rather at the first feasible location at the top of
the page. Where it is feasible, this should come in the form of a text entry in
the product highlights. Otherwise, it should be added to the first product
image immediately viewable to a consumer on the product listing page. Where the
disclaimer is included at the top of the listing page in the product
highlights, Joneca need not also include the disclaimer in the first product
image.

Some of Joneca’s online disclaimers are not immediately
viewable to consumers on a product’s landing page and thus Joneca hadn’t taken
all reasonable steps to bring these product listings into compliance. Joneca argued
that the various online product listing policies of its retailers prevented
compliance. “But nowhere in Joneca’s declaration does it claim to have
requested a variance from any retailer’s listed policy or otherwise sought an
accommodation in light of this Court’s Order…. The potential for accommodation
is underscored by InSinkErator’s submission of images of product listings from
Home Depot’s website with text in the first image, despite the plain language
of its policy disallowing such text.”

Thus, “Joneca must work with its retailers to modify the
location of the disclaimer to conform to the above requirements in order to
come into compliance with the preliminary injunction.” However, the court
declined to find Joneca in civil contempt because it applied its initial
disclaimer pursuant to each retailer’s online listing policy in good faith.

A footnote worried about AI page changes [yes, now every
compliance person should have the same worries!]: “[T]o the extent a listing on
Amazon or Walmart comes out of compliance, such as because of an AI-generated
text box, Joneca should work with the retailer to include the disclaimer per
the criteria listed.”

from Blogger https://tushnet.blogspot.com/2026/04/court-gives-guidance-on-disclaimer.html

Posted in Uncategorized | Tagged , | Leave a comment

former TM owner states valid damages claim against licensee of current TM owner that drove it out of business via infringement

Wagner Zip-Change, Inc. v. Tubelitedenco, No. 23 C 05077, 2026
WL 673148 (N.D. Ill. Mar. 10, 2026)

Wild facts! Wagner was until 2021 in the business of selling sign
lettering products, including its trademarked Jewelite Trim (also known as
“trim cap”), “a plastic molding that adds dimension to cut-out sign letters.” It
obtained an exclusive license to use the mark in 1987. It contracted with a
third party, Vidon, for manufacture, and sold its products to distributors,
which then sold them to sign companies and other end users. Defendants were
among the largest distributors.

Vidon allegedly began manufacturing a knock-off version of
Jewelite Trim. Tubelite then allegedly entered into a distribution agreement
with Vidon. Tubelite allegedly (1) made false and misleading statements that
Vidon’s knock-off trim cap was “the original trim cap,” that Vidon was just a
“different name” for Jewelite, and that the product was “the exact same”; (2)
used the Jewelite mark in connection with the sale and promotion of the Vidon
trim product; and (3) filled at least several hundred customer orders for
“Jewelite,” “Wagner Jewelite,” and “Wagner” trim cap with the Vidon product. Tubelite’s
conduct allegedly “contributed greatly” to driving Wagner out of business,
resulting in at least $4.5 million in lost sales. Wagner ultimately gave up its
rights in the Jewelite mark, which was then assigned to Vidon.

Wagner sued Tubelite for violations of the Lanham Act and
state law claims for unfair competition and tortious interference with
prospective economic advantage.

Under these circumstances, the court rejected Tubelite’s
argument that, though its use of the mark was confusing, Wagner couldn’t sue because
(1) it’s not the current user of the mark and (2) Vidon is the mark’s current
owner.

Wagner was suing for damages, not an injunction. Violation
of its past rights gave it a cause of action. Cases requiring use for trademark
rights “simply stand for the proposition that a plaintiff claiming infringement
must show that it had rights in the mark when the alleged infringement took
place.” It was enough that “Wagner had enforceable rights in the mark when
Tubelite used it to sell Vidon’s products.”

For statutory standing, a plaintiff must (1) “allege an
injury to a commercial interest in reputation or sales” that (2) “flow[s]
directly from” the defendant’s violation of the statute. “Wagner easily
satisfies that test, alleging (1) a commercial injury (loss of millions in
sales) that (2) directly resulted from Tubelite’s misleading use of the
Jewelite mark.” Nothing in Lexmark required a plaintiff to show
current rights in the mark or likelihood of a future injury. “Nor would that
requirement make much sense. Consider the consequences: defendants who
appropriate another party’s mark so successfully as to actually drive that
party out of business—as Tubelite is alleged to have done here—would
effectively be immune from suit under the Lanham Act. That would be an
exceedingly odd result.” Indeed, Lexmark itself commented that “a
competitor who is forced out of business by a defendant’s false advertising
generally will be able to sue for its losses.”

Tubelite also unsuccessfully argued that Wagner’s false
association claim fails because Vidon, as the Jewelite mark’s current owner of
record, has an incontestable right to use the mark. Incontestability had
nothing to do with the issue here. Vidon acquired the mark after the alleged
misuse of the mark took place. [Maybe Vidon has such a right, but it didn’t
have such a right.] “Second, Tubelite—not Vidon—is the defendant in this
action, and it has presented no legal authority to suggest that it can assert
Vidon’s rights in its own defense.” Anyway, there were lots of exceptions to incontestability.

Sometimes dumb arguments make for bad explanations that omit
nuance, but sometimes they lead courts to articulate the reasons for the rules,
and that’s nice.

from Blogger https://tushnet.blogspot.com/2026/04/former-tm-owner-states-valid-damages.html

Posted in Uncategorized | Tagged | Leave a comment

delay still defeats Lanham Act presumption of irreparable harm

Skillz Platform Inc. v. Voodoo SAS, 2026 WL 717220, No. 24-CV-4991
(VSB) (JW) (S.D.N.Y. Feb. 12, 2026)

Skillz sought an injunction against defendants’ allegedly
false representations about not using bots, and against defendants’ use of bots,
in their gaming applications. Skillz has showed up before litigating against
other gaming companies’ bot-related representations. Its games including those
where players can compete to win cash prizes in head-to-head, skill-bracketed
tournaments that ban bots. Defendants run similar games and advertise
themselves as, e.g., “fair” and “skill-based” games that are played against
“real players” with “no bots allowed.”

The magistrate recommended against an injunction solely on
grounds of delay. The relevant date for measuring delay was not the filing of
the initial complaint, but at the time Skillz learned of the alleged harm. Even
after filing, it waited seven weeks to move for a preliminary injunction.
Without more evidence about when it first learned of the bot use, this
“undercuts the sense of urgency that ordinarily accompanies a motion for
preliminary relief and suggests that there is, in fact, no irreparable injury.”

In addition, the claims of irreparable injury were too
remote and speculative to justify emergency relief. Although the parties do compete,
Skillz didn’t show a logical causal connection between the alleged false
advertising and (1) its own sales position or (2) the overall cash gaming
market.

Skillz showed that its sales and market share decreased
since 2021, but not that the alleged false advertising played any role in that
beyond unsupported speculation by a self-serving declaration. So too with harm
to the overall market. “Courts in this circuit have frequently rejected such
speculative arguments in deciding whether to issue a preliminary injunction.”
[Now do trademark infringement!]

Without evidence of harm to Skillz’ own reputation, as
opposed to allegations that distrust was harming the overall market, money
damages could redress any injury.

from Blogger https://tushnet.blogspot.com/2026/04/delay-still-defeats-lanham-act.html

Posted in Uncategorized | Tagged , | Leave a comment

damages requirement trips up another false advertising case with sophisticated customers

Agilent Technologies, Inc. v. Axion Biosystems, Inc., 2026
WL 734986, No. 23-198-CJB (D. Del. Mar. 12, 2026)

Agilent alleged patent infringement and false advertising by
Axion in the advertising of its impedance-based cell assay products. E.g., “The
simple and sensitive assays of the Maestro Z accurately measure tumor growth
and immune cell killing of 3D cancer spheroid models.” Agilent contended that
the Maestro Z platform doesn’t actually accurately measure the impedance of 3D
spheroids, but only of cells in contact with electrodes on a 2D surface. 

The court granted Axion’s summary judgment motion. Even
assuming a genuine dispute on literal falsity and on whether the statements
were fact, not opinion, Axion still prevailed.

“For a false advertising claim seeking injunctive relief, if
a plaintiff can prove the statement in question is unambiguous and literally
false—then actual deception or a tendency to deceive is presumed and need not
be proven.” However, “where a plaintiff seeks only money damages for a Lanham
Act violation”—regardless of whether the plaintiff is asserting that the
statements are literally false or simply misleading—then “plaintiff must
present proof of actual deception.” Axion sought both an injunction and money
damages; for the injunction, actual deception could be presumed.

But there was not enough evidence of actual deception for
misleadingness or damages. A consumer survey or other customer testimony “is
not absolutely required if other evidence of actual customer deception exists.”
Agilent’s own corporate representative testified about the purported experience
of a prospective customer, but this was double hearsay, not admissible at
trial. [Agilent apparently didn’t respond that this was evidence of state of
mind subject to an exception.] She “could not recall [any] specific case” of
customers saying that they wanted the feature at issue. “This vague testimony
amounts to a conclusory assertion backed by no actual facts on the key point in
dispute.” Nor did the court’s reading of the record support the idea that
“Axion’s own collaborators, … who Axion stated are ‘representative of an Axion
customer,’ were deceived.” Given their extensive experience with the products, “whatever
views they came to regarding Axion’s products and their capabilities were
surely gleaned from their own extensive research efforts.”

Thus, claims requiring actual deception failed. The
remaining claim (literal falsity/injunctive relief) failed for want of a
showing of injury.  

Agilent’s damages theory wasn’t based on any lost sales
or reputational damage, and instead focused solely on prospective corrective
advertising costs. The Third Circuit “does not place upon the plaintiff a
burden of proving detailed individualization of loss of sales” as “[s]uch proof
goes to quantum of damages and not to the very right to recover.” And the
parties compete directly. Still, there was no real evidence of harm: the
testimony was “so vague, conclusory, and/or inadmissible that it cannot be good
evidence of anything.” [Now do trademark infringement!]

from Blogger https://tushnet.blogspot.com/2026/04/damages-requirement-trips-up-another.html

Posted in Uncategorized | Tagged | Leave a comment

drug makers face rocky road in making claims against sellers of compounded weight loss drugs

Three different cases reading Lexmark differently but mostly kicking out claims:

Eli Lilly & Co. v. Aios, Inc., 2026 WL 836624, No.
25-cv-03535-HSG (N.D. Cal. Mar. 26, 2026)

Eli Lilly sells Mounjaro and Zepbound, GLP-1 inhibitors
containing tirzepatide. These are the only FDA-approved medicines containing
tirzepatide in the United States, and the FDA has not approved any tirzepatide
product in oral or compounded form.

Defendant operates telehealth platforms focusing on drugs
for weight loss, including compounded tirzepatide. Eli Lilly alleged that its
Fella telehealth platform engaged in the unlicensed practice of medicine: For
example, the non-physician founder allegedly “frequently tells customers that
he can help increase their dosage amounts of Fella’s knockoff drugs if they
contact him or his non-physician customer success team directly.” Fella also
allegedly changed patient prescriptions “en masse,” based on Fella’s business
needs, rather than individualized patient needs. Many patients allegedly
learned that their prescription now contained an additive “not through their
doctor but rather when their prescription arrived from Fella Health.” Eli Lilly
alleged that these weren’t “personalized prescriptions”—rather, Fella is
offering “an untested, unapproved, one-size-fits-all drug” to patients without
complying with the California Medical Practice Act’s requirement that
prescriptions be made with “an appropriate prior examination and a medical
indication.”

Eli Lilly also alleged deceptive conduct with claims such as
“[o]ur science-backed methodology delivers results that outperform traditional
weight loss methods”; “[o]ral tirzepatide is the same active ingredient as the
compounded injectable (tirzepatide)”; and “[o]ur advanced oral Tirzepatide
treatment, developed through cutting-edge research, offers a safe and effective
solution tailored to support your weight loss journey and overall health.”

Eli Lilly alleged that Fella knew these statements were
false. In a Reddit post, Fella’s Head of Customer Sales wrote that “oral
[tirzepatide] can be fairly ineffective (though not totally ineffective), and
some may experience more GI discomfort due to daily administration.” One of
Fella’s customer success leads wrote that “[t]he oral version is less effective
than the injectables, but it’s still better than not being on the medication at
all.” Fella’s founder wrote on Reddit that “oral [tirzepatide] is slightly less
effective than subcutaneous.”

But Fella’s website states that oral tirzepatide is
“science-backed” and that Fella uses a “science-backed methodology,” while its
Head of Customer Sales wrote that patients generally lose 15% of their body
weight in one year on oral tirzepatide. Eli Lilly alleged that oral tirzepatide
has never been studied in clinical trials and that Fella has no science at all
supporting its oral product. The statistic cited by Fella on its
female-targeted Delilah website, that patients using oral tirzepatide experience
a weight loss average of “22.5%,” was derived from Eli Lilly’s clinical trial
on injectable tirzepatide, not oral or compounded tirzepatide.

Eli Lilly sued for violations of the UCL, FAL, and Lanham
Act, along with civil conspiracy.

Fella argued that Lilly lacked standing because they weren’t
competitors and Eli Lilly couldn’t allege “something very close to a 1:1
relationship between [Eli Lilly’s] lost sales and the sales diverted to a
defendant.” The court disagreed: Lexmark directed the court to use the zone of
interests test and proximate cause, both of which Lilly properly alleged.

Lilly alleged that “Fella’s unfair, deceptive, misleading,
and false practices, including its false and misleading statements, cause
irreparable harm to Lilly’s brand and customer goodwill by promising results
that consumers cannot obtain from Fella’s product,” and, because Fella relied
on Lilly’s studies on its product, consumers would also think that Lilly’s
product would be that bad. Plus, Lilly alleged injury to its commercial
interest in sales. E.g., on Reddit, one of Fella’s customers said he “was on zepbound”
until mid-November 2024, but “stopped” when the medicine became too expensive
and eventually switched to Fella. Lilly also had standing under the UCL and
FAL, but only as to false advertising, not to the UCL claim based on allegedly
unlawful corporate practice of medicine. “Eli Lilly does not plausibly allege
how Defendants’ claimed lack of authorization to practice in itself causes it
any injury.”

Commercial advertising or promotion: It was plausible that
the Reddit posts were made for the purpose of influencing customers to buy
Fella’s products. Although this was a closer question than statements on
Fella’s own website, the Reddit statements “tout Fella’s success with
statistics, refer to Fella’s oral and injectable tirzepatide products, and
adequately reflect an economic motivation, such that the allegations support a
reasonable inference that ‘the economic benefit was the primary purpose for speaking.’”

However, Lilly struggled with its literal falsity arguments,
since “lack of substantiation” is not itself a valid theory under state or
federal law. For example, Lilly alleged that Fella’s statements regarding its
patients typically losing 15-22.5% of their body weight were false because
those statements are in reality based on the results of Eli Lilly’s clinical
trials, which were performed on injectable and non-compounded tirzepatide. And
it’s true that a plaintiff can show falsity by showing that even reliable tests
do not establish the proposition asserted by the defendant. “But here, Eli
Lilly has not alleged that Fella made any representation regarding the specific
basis for its statements about the weight loss results typically achieved for
its patients, and Eli Lilly does not allege any contrary facts (as opposed to
the purported lack of supporting facts).” Lilly didn’t plausibly allege that
Fella’s statements about the existence of rigorous “research” and “testing”
were false just because oral tirzepatide has never been subject to the
particular mechanism of a clinical trial or study. [Seems like a consumer
survey should be relatively easy to do to find deceptiveness even if not
literal falsity.]

The only allegedly false statements sufficiently pled were
those made in connection with Fella’s promotion of “personalized treatment
plans.” Whether defendants actually personalize customers’ treatment was
capable of being proven true or false, not puffery.

Novo Nordisk A/S v. Amble Health, Inc., No. 4:25-CV-01048, 2026
WL 776100 (N.D. Ohio Mar. 19, 2026)

The parties allegedly are competitors in the sale of drug
products containing semaglutide. Novo Nordisk sells the only FDA-approved
medicines containing semaglutide in the United States, Amble is a telehealth
company that sells drugs purportedly containing semaglutide, produced at
compounding facilities. Novo Nordisk alleged that these compounded drug
products are mass produced and create a higher risk to patients than Novo
Nordisk’s medicines, because the FDA does not conduct pre-market reviews of compounded
drugs for safety, quality, or effectiveness.

The complaint also alleged that Amble’s ads falsely claims
that its drugs are personalized: “tailored to you,” and are “tailored to your
personal goals,” with “personalization” of “active ingredients, dosage, and
form of a medication to meet an individual’s personal needs.” The complaint
alleged that, to the contrary, the compounded drugs were “ordered in bulk and
sold to patients off the shelf.”

The court found that Novo Nordisk didn’t plausibly allege
injury in fact. The complaint alleged sales diversion as well as reputational
harm because compounded drugs might “undermine the reputation for quality and
safety established on Novo Nordisk’s FDA-approved medicines.”

But defendants’ use of “personalized” didn’t plausibly threaten
to harm Novo Nordisk’s reputation. “At base, [Plaintiff] appears to argue the
mere fact a medication is compounded makes it an inferior version of an
FDA-approved product with the same active pharmaceutical ingredients. But
compounding is a federally recognized and regulated pharmaceutical practice ….”
Novo Nordisk needed at least facts supporting an inference that Amble’s compounded
medication fails to meet consumer expectations, which it didn’t. Nor did it
plausibly allege that any of Amble’s customers were harmed by the compounded
medication “such that they could draw unwarranted conclusions about the safety
and efficacy” of Novo Nordisk’s drugs.  Although Novo Nordisk pled that “the FDA has
received reports of adverse events, some requiring hospitalization related to
overdoses from dosing errors associated with compounded ‘semaglutide’ products,”
dosing errors don’t show that the term “personalized” in and of itself has led
to any patient diversion. [The court is weirdly going back and forth between
reputation and sales diversion.]

Even with Article III standing, Novo Nordisk didn’t properly
allege statutory standing via the proximate cause element: The “personalized”
message didn’t plausibly cause the harm. Compounded medications require prescriptions,
and the physician’s prescribing decision, not the ads, was the proximate cause
of the patient using the compounded medication instead of Novo Nordisk’s
product.

Eli Lilly & Co. v. Willow Health Services, Inc., No.:
2:25–cv–03570–AB–MAR, 2026 WL 639976 (C.D. Cal. Feb. 3, 2026)

Eli Lilly alleged its medicines are backed by rigorous
science and quality controls. It has FDA approval for two injectable tirzepatide-based
medicines. At the time of the complaint, there was no FDA-approved oral
tirzepatide. Willow operates a telehealth platform that markets and sells
weight-loss treatments directly to consumers. Willow offers compounded
tirzepatide products, including an injectable formulation and an oral
formulation.

The FDA allegedly has expressed particular concern about
compounded GLP-1 drugs, many of whose components are manufactured by facilities
that are not subject to the same regulatory oversight as domestic
manufacturers. It has warned about dosing errors, adverse events, and the use
of unapproved salt forms in compounded tirzepatide products. 

Willow allegedly marketed its products as clinically
validated and comparable to, or superior to, Lilly’s FDA-approved medicines: that
its tirzepatide treatment has undergone “extensive testing,” is supported by
“science,” and produces significant weight loss outcomes. Imagery of physicians
and references to board-certified doctors allegedly reinforced the impression
of medical endorsement.

Willow also allegedly claimed that its product is a
“premium” blend that delivers “better results” than tirzepatide generally. Then
it reiterates that its medication undergoes extensive testing. Lilly alleged
that, in fact, Willow has no clinical studies supporting these claims, and no
testing has been conducted on Willow’s compounded products to demonstrate
safety or effectiveness. 

Willow allegedly marketed its drops as effective and, at
times, superior to injections, but no clinical data supported the effectiveness
of any oral tirzepatide product.

And Willow allegedly misrepresented that its medications were
custom, “personalized,” and tailored to each patient’s unique needs, rather
than standardized formulations delivered to all patients. Willow’s intake
questionnaire “purports to assess whether Willow’s treatment is appropriate”
but recommends its medication to all users regardless of the information
provided.

After Lilly sued, Willow added a disclaimer to its website
stating that its products are not FDA-approved and have not undergone clinical
trials, but Lilly alleged that this bottom-of-page statement didn’t affect the
overall message. Lilly also alleged that survey conducted by the National
Consumers League found that many consumers incorrectly believe  thatcompounded GLP-1 drugs are FDA-approved
and clinically tested. Willow’s advertising allegedly mirrored the types of
statements the FDA has identified as false and misleading in warning letters
sent to compounders and telehealth companies: “clinically proven,” “backed by
extensive clinical research,” and “personalized.”

Lilly alleged that Willow’s marketing falsely equates its
untested compounded products with FDA-approved medicines, diverting sales and
harming Lilly’s reputation. It further alleged that adverse events associated
with compounded tirzepatide products are often mistakenly attributed to Lilly’s
medicines, further damaging its goodwill.

Statutory standing: “[T]he test forecloses suit only when a
plaintiff’s interests are so marginally related to or inconsistent with the
purposes implicit in the statute that it cannot reasonably be assumed that
Congress authorized the plaintiff to sue.”

“If the plaintiff can demonstrate that the defendant is a
direct competitor, there is a presumption of a commercial injury to plaintiff
sufficient to establish standing.” Willow argued that wasn’t a direct
competitor of Lilly evidenced by the fact that Lilly didn’t have direct
evidence of lost sales and it actually had an increase in sales of Mounjaro and
Zepbound. Lilly argued that the presumption of commercial injury conferred by
direct competition couldn’t be rebutted. [Gotta say, that seems correct for the
motion to dismiss stage.]

The court recognized “a split of authority in the Ninth
Circuit on whether a presumption of commercial injury arising from direct
competition is sufficient on its own to establish standing, or whether a
plaintiff must also allege concrete facts demonstrating lost or diverted sales.”

Lilly alleged that Willow’s conduct “results in potential
patients being lured away” and that “Willow[’s] … materially false statements
… influence consumers’ … decision to purchase Willow’s [drugs] instead of
Lilly’s FDA-approved medicines.” Lilly also alleged that the products compete
at “similar prices” causing consumers make purchasing decisions “based on
factors other than pricing, including comparative safety and effectiveness.” These
allegations, together with the presumption arising from direct competition, were
sufficient to plead commercial injury.

What about proximate cause? A plaintiff “ordinarily must
show economic or reputational injury flowing directly from the deception
wrought by the defendant’s advertising; and that that occurs when deception of
consumers causes them to withhold trade from the plaintiff.” Proximate
causation may be adequately alleged when “there is likely to be something very
close to a 1:1 relationship between” a plaintiff’s lost sales and the sales
diverted to a defendant.

The court seems to read this Lexmark quote as a requirement
rather than an example. But if I plausibly allege that my competitor & I
would likely have split the sales garnered by a competing false advertiser, it’s
got to be the case that I have standing. It’s not the 1:1 relationship that
creates proximate causation but that, although the parties are at distinct
parts of the value chain (as the parties were in Lexmark), a 1:1 sales
relationship can justify finding proximate causation—a legal rather than
factual conclusion—at a greater competitive distance than a more unbalanced/hard-to-prove
loss ratio would have.

Reading Lexmark that restrictively, Lilly still
failed to plead “a direct causal link between any advertisement by Willow and a
patient choosing a compounded medication over Lilly’s product.” “Critically,
regardless of advertising or patient intent, obtaining a prescription
medication requires a physician to prescribe it. The physician’s prescribing
decision, not Willow’s advertisements, is the proximate cause of the patient
using the compounded medication instead of Lilly’s product.”

Lilly objected in vain that this ruling would categorically
eliminate Lanham Act claims for prescription drugs. You still need “allegations
showing a direct link between advertising and lost sales,” taking into account “the
fact that prescriptions, a foreseeable and legally required step, determine
whether a patient can actually obtain the product.” [Honestly, I’m not sure how
hard this would be for Lilly to plead. The whole point of these services is
that they contract with doctors to prescribe exactly what the services offer. A
patient who contacts a doctor through one of these services is extremely likely
to end up with their products. I don’t think Lilly should have to plead it, but
it seems very plausible.]

from Blogger https://tushnet.blogspot.com/2026/04/drug-makers-face-rocky-road-in-making.html

Posted in Uncategorized | Tagged , | Leave a comment

CEO/sole owner is liable to bankruptcy estate for deliberate false advertising campaign that ended in bankruptcy

In re Vital Pharmaceuticals, Inc. (VPX Liquidating Trust v.
Owoc), 2026 WL 822473, No. 22-17842-PDR, Adv. Pro. No. 24-01009-PDR (Bkrcy.
S.D. Fla. Mar. 24, 2026)

This is an interesting case about false advertising and
individual officer liability in bankruptcy. The court begins:

Corporate officers who breach their
fiduciary duties do not become immune from accountability simply because they
are also the only stockholders. Florida law imposes fiduciary obligations on
directors and officers for the protection of the corporation itself—not for the
benefit of any particular class of shareholders, and not subject to waiver by a
sole owner who later finds it convenient to argue that no one was harmed but
himself. When those obligations are breached and the corporation is driven into
bankruptcy, the right to enforce them passes to the trustee or liquidating
trust.

Owoc was VPX’s founder, sole shareholder, sole director, and
CEO. A jury found that his and VPX’s false advertising of energy drinks was willful
and deliberate, resulting in a judgment approaching $300 million.

At its peak, VPK generated over $1 billion in annual revenue,
but its commercial success was based on claims about a proprietary ingredient that
Owoc called “Super Creatine.” VPX falsely advertised that it offered
significant physical and mental health benefits. VPX had “no corporate will
separate from Mr. Owoc’s own.”

Because the jury was instructed that “VPX and/or Mr. Owoc
acted willfully if they knew that their advertising was false or misleading or
if they acted with indifference to whether their advertising was false or
misleading,” its willfulness finding “necessarily encompassed a determination
that Mr. Owoc either knew that the advertising was false or acted with
indifference to whether it was.”

The judgment was one of the principal reasons for VPX’s
bankruptcy filing; the resulting trust sought to hold Owoc liable for breach of
fiduciary duty arising from the false advertising.

This claim requires: (1) the existence of a fiduciary duty;
(2) a breach of that duty; and (3) damages proximately caused by the breach.
Collateral estoppel applied to prevent Owoc from relitigating whether he
willfully and deliberately engaged in false advertising of Super Creatine.

As VPX’s sole director and CEO, Owoc owed VPX fiduciary
duties of care, loyalty, and good faith. A breach under Florida law requires at
least gross negligence, which is “synonymous with engaging in an irrational
decision making process.” The false advertising jury’s findings were
preclusive: “A director who causes the corporation to engage in a years-long
false advertising campaign that he knew was false, or acted with indifference
to whether it was false, is the precise ‘knowing and deliberate indifference to
the potential risk of harm to the Company’ that … breaches the fiduciary duty
of care.” The damages were the judgment entered against VPX. Thus, there was
liability (quantification of damages was for later).

The court rejected Owoc’s arguments, including that VPX was in
pari delicto (equal fault) with him and thus barred from making the breach
claim. The court disagreed: the doctrine “is not a tool for the powerful to
insulate themselves from the consequences of their own misconduct.” It was
designed for situations when two parties were independently at fault,
voluntarily engaged in the same wrongdoing, and then fought about their
relative entitlements arising from that shared wrongdoing. “In that situation,
a court steps back and says: we will not sort this out.” It follows that, “when
the parties were not independently at fault, when the plaintiff was not a
voluntary wrongdoer, or when the very nature of the claim is that the defendant
wronged the plaintiff rather than that both wronged each other,” the doctrine
doesn’t apply. That was the case here.

While a bankruptcy trustee cannot sue third parties for
their role in wrongdoing if the corporation itself was an equal participant
(given that corporations can’t act without individual humans so the humans’ wrongdoing
is attributed to the corporation), “an agent’s misconduct is not imputed to the
principal if the agent was acting entirely in his own interest and adversely to
the interest of the corporation.” “VPX’s liability in the Monster False
Advertising Litigation was the legal consequence of Mr. Owoc’s own conduct
being attributed to the entity he wholly controlled. The jury’s finding of
willfulness against VPX reflects Mr. Owoc’s willfulness, not some independent
institutional decision by VPX to deceive.”

Allowing Owoc to point to the fact that the law attributed
his acts to VPX as a shield against accountability to VPX would be “to let
fiduciaries immunize themselves through their own wrongful, disloyal acts—a
“transparently silly result.” And if Owoc could do it here, so could every sole
owner-operator, which would “systematically immunize the most powerful actors
in closely held corporations from the most fundamental obligations corporate
law imposes on them.”

Nor did the business judgment rule protect Owoc because of
the breach of fiduciary duty. “This is not a case of a business judgment gone
wrong — a risky but good-faith marketing strategy that backfired. It is a case
of a director who caused his corporation to make claims he knew were false or
misleading, or acted with indifference to whether they were false or
misleading. The rule was not designed to shield such behavior.”

from Blogger https://tushnet.blogspot.com/2026/04/ceosole-owner-is-liable-to-bankruptcy.html

Posted in Uncategorized | Tagged | Leave a comment

court dismisses vague false advertising counterclaims but allows challenge to Wonderful’s pistachio trade dress

Wonderful Co. v. Nut Cravings Inc., No. 1:21-cv-03960 (MKV),
2026 WL 818073 (S.D.N.Y. Mar. 24, 2026)

Wonderful sued Nut Cravings for infringing its pistachio package
trade dress. This opinion deals only with Nut Cravings’ counterclaims, which
mostly survive except for false advertising.

Wonderful has a registration for its packaging: a design
“consist[ing] of black three-dimensional product packaging having a rectangular
shape with transparent semi-circular curved sides, the word ‘WONDERFUL’ in
white with a design of a ‘heart’ in place of the letter ‘O’ appearing across
the top of the packaging and the word ‘PISTACHIOS’ in green appearing
vertically in the middle of the packaging” for “processed nuts.”

It also claimed unregistered trade dress in: (1) “a
predominantly black package”; (2) “a bright green accent color”; (3) “use of
sans serif font for the word ‘PISTACHIOS’ ”; (4) “use of capital letters for
the word ‘PISTACHIOS’ ”; (5) “semi-circular curved ‘window’ cut outs showing
pistachios”; and (6) “the WONDERFUL mark.”

Nut Cravings uses a black and green color scheme for its
pistachios, has the phrase “roasted salted pistachios” written in all capital
letters, a sans-serif typeface, and a rectangular simulated-window on the front
of its package. It alleged that each of the elements that overlap with Wonderful’s
is generic and functional for packaging of processed nuts.

Nut Cravings plausibly alleged that the trade dress
(registered and unregistered) was functional, thus stating a claim for
invalidity of the registered mark. Although a combination of functional
elements can in theory be nonfunctional, “the fact that a trade dress is
composed exclusively of commonly used or functional elements might suggest that
that dress should be regarded as unprotectable or ‘generic,’ to avoid tying up
a product or marketing idea” (also citing Laurel Road Bank v. CommonBond, Inc.,
18-cv-7797 (ER), 2019 WL 1034188, at *6 (S.D.N.Y. Mar. 5, 20219) (noting that
“where each element is functional and the elements work in tandem to create an
advertisement that is readable and eye-catching, [plaintiff] is not likely to
meet its burden that the Trade Dress is nonfunctional”)).  

The counterclaim plausibly alleged that only the Wonderful
mark was nonfunctional. The presumption of nonfunctionality afforded by
registration is rebuttable. Nut Cravings alleged that black and green provide a
non-reputation related benefit of an aesthetically pleasing appearance, with
black separately indicating high quality and green separately indicating the
product is related to “nature, health and/or pistachios.” It cited pleading
numerous reports and publications explaining the benefits of the use of these
colors for food packaging. It further alleged that numerous other processed nut
products use green and black for their packaging and provided 36 specific
examples.  “[A] color on packaging may be
functional in a given industry.”

Nut Cravings also alleged that the other elements—capital
letters, sans-serif font, and transparent windows on the package—are functional
and provide non-reputation related benefits for food packaging. All-caps is
allegedly commonly used to denote simplicity and/or premium quality; sans-serif
font is allegedly commonly used to assist readability; transparent windows are allegedly
commonly used to “entic[e] customers, enhance[e] product visibility, and/or
display[ ] the freshness of items inside.” These are all non-reputation-related
benefits that courts have found to be functional in similar contexts. E.g., Laurel
Road Bank
found the use of sans serif font in advertising campaign to be
functional as it “enhanced legibility and readability” and that the use of
“large text catches a viewer’s attention” and is also functional, and Kind LLC
v. Clif Bar & Co., 2014 WL 2619817, (S.D.N.Y. June 12, 2014), held that the
use of a transparent window on food packaging for food bars serves a functional
purpose “of revealing the bar within.” In reversing the dismissal of Wonderful’s
claims in this case and finding nonfunctionality plausible, the Second Circuit even
noted that “the transparent windows in the packaging [ ] arguably serve the
functional purpose of allowing a consumer to view the pistachios being sold.”  

So too with genericity, although the allegations were
thinner. That’s what discovery is for.

False advertising: Nut Cravings alleged that Wonderful misrepresented
that the packages contain more edible pistachios than actually included. It pointed
to nineteen online consumer reviews complaining of a significant number of
empty shells in Wonderful pistachio products. Nut Cravings alleged that
consumers expect that packages of in-shell processed nuts will include
substantially only editable nuts within shells, and that “almost all of the
advertised weight” is edible, and that the deception here caused consumers to
pick Wonderful over Nut Cravings.

But conclusory allegations that false advertisements caused a
claimant to lose sales are insufficient. None of the cited customer reviews
mentions Nut Cravings or says that the customer otherwise would have purchased
from them absent the allegedly false statements.  Nut Cravings didn’t even allege that every bag
misrepresents its net weight due to a significant number of empty shells. The
court wasn’t willing to give every pistachio producer a claim against Wonderful
without more allegations.

from Blogger https://tushnet.blogspot.com/2026/04/court-dismisses-vague-false-advertising.html

Posted in Uncategorized | Tagged , | Leave a comment

Meta’s AI assistance to advertisers defeats Section 230, court says

Bouck v. Meta Platforms, Inc., No. 25-cv-05194-RS (N.D. Cal.
Mar. 24, 2026) 

Does offering AI enhancements to deceptive ads constitute
participating in what makes them illegal for purposes of avoiding section 230?
This case answers “yes, relatively easily” and it should be raising flags in a lot of
boardrooms.

Plaintiffs here are victims of a pump-and-dump scheme
involving shares of a Chinese penny stock. The scammers initially targeted them
on Facebook and Instagram through advertisements for investment groups
promising handsome returns. For example, in one ad, Kevin O’Leary— “a
businessman well-known for his role on Shark Tank”—appears to advertise a
private group in which stock tips are shared. In another, Savita
Subramanian—Bank of America’s head of U.S. equity and quantitative strategy—
“looks to be promoting” spots in a “free trading training” group that boasts
“95% accuracy” and 30-40% daily returns. 

Plaintiffs sued Meta for aiding and abetting fraud;
negligence; breach of contract; violation of the California Unruh Civil Rights
Act, Cal Civ Code § 51; and unjust enrichment, along with promissory estoppel
and breach of the covenant of good faith and fair dealing as alternatives to
their breach of contract claim. The court allowed the claims for aiding and
abetting fraud, negligence, and unjust enrichment to proceed.

Section 230: An “information content provider” is “any
person or entity that is responsible, in whole or in part, for the creation or
development of information provided through . . . any other interactive
computer service.” If Meta was sufficiently involved in the “creation or
development” of the fraudulent ads, the court reasons, then those ads were not
just “provided by” the scammers—they were also provided by Meta. Under 9th
Circuit precedent, a website helps to develop unlawful content “if it contributes
materially to the alleged illegality of the conduct.”

Plaintiffs’ allegations of material contribution depended on
three tools Meta offers to advertisers. (1) Flexible Format: “Meta
automatically optimizes the ad and shows it in the format that Meta predicts
may perform best” by “selecting the specific images and other content that will
be included, the layout, the platform (Facebook or Instagram), and how the ad
will be displayed to a particular user (e.g., in the user’s feed, as a story,
etc.).” (2) Dynamic Creative: This tool “takes multiple media, such as images
and videos, and multiple ad components, such as images, videos, text, audio,
and calls-to-action, and then mixes and matches them in new ways to improve . .
. ad performance.” This “allows the advertiser to automatically create
personalized creative variations for each person who views the ad, with results
that are scalable.” (3) Advantage+ Creative: Meta uses generative AI to apply
“creative enhancements” to optimize advertisements, including AI-generated text
and images. “The alterations may include modifications to images (such as
applying different text overlays or modifying the image background), generating
variations of the ad’s text to target different audiences, and inserting ‘Call
to Action’ buttons, such as a link to purchase a product or join a WhatsApp
group.”

The complaint alleged that scammers used these tools at
least to create different variations of ads featuring Ms. Subramanian. That was
enough to plead the existence of a dispute over whether Meta “contribute[d]
materially to the alleged illegality of the advertisements.” “Plaintiffs have
averred that Meta participated in the construction of the ads by literally
generating, using artificial intelligence, the images and text in the
advertisements. That degree of participation is not protected by section 230.”
In other words, “optimizing the appearance of an ad to drive engagement” was
enough of a contribution to the ads’ illegality to preclude section 230
immunity. Pleading the ability to create “AI- generated text and images” “is
more than enough to aver ‘that the tools affect ad content in a manner that
could at least potentially contribute to their illegality.’”

Meta argued that its tools were “neutral” and that offending
content was exclusively provided by the scammers. But 230 allows services to
“structure the information provided by users,” not “to create the information
itself.” Plaintiffs alleged that “Meta created the offending information by
generating some of the false statements that tricked them into the investment
scheme.”

If a scammer tells Advantage+ Creative “that he is
interested in an ad promising astronomical weekly investment returns,
Advantage+ Creative will spin up a slew of ads that include the provided
language and other language, images, and videos it decides will be effective in
promoting the user’s chosen message.” Indeed, a journalist from Reuters asked
for an ad asking users if they were “interested in making 10% weekly returns.”
Advantage+ Creative “generated a slew of ads saying just that and new ads with
language like ‘Tired of living paycheck to paycheck? Break the cycle and start
earning steady weekly income with our proven system.’ The reporter did not come
up with that (patently fraudulent) language; it was all Meta.” It was at least
plausible that some of the illegal content (i.e., the fraudulent statements in
the ads) was created by Meta, not by the scammers.

Aiding and abetting fraud: “California has adopted the
common law rule that [l]iability may … be imposed on one who aids and abets
the commission of an intentional tort if the person … knows the other’s
conduct constitutes a breach of a duty and gives substantial assistance or
encouragement to the other to so act.” Meta argued that it neither had
knowledge of the scammers’ conduct nor substantially assisted in the execution
of their scheme. Plaintiffs alleged that Meta has been repeatedly subject to
lawsuits stemming from similar schemes; that Meta itself acknowledged the
proliferation of fraud using public figures and celebrities’ images; and that
Meta had an “ad review system” in place to screen ads for “violation of
[Meta’s] policies.”

Meta responded that knowledge that fraud is occurring
generally on its platforms could not have given “actual knowledge of the
specific primary wrong” at issue in this case. “In a vacuum, that argument has
merit. Under California law, knowledge that something illegal is occurring on a
defendant’s platform does not establish that the defendant knew of the
particular illegal conduct that injured the plaintiff.” But the court accepted
allegations “that when Meta saw the ads in its ad review process, Meta acquired
actual knowledge of their fraudulence.”

What about the moderator’s dilemma?  “To be sure, in many cases a defendant could
not be charged with actual knowledge of fraud simply because the fraud passed
through a routine review process. For that reason, many cases arising in the
financial fraud context have required a plaintiff bringing an aiding and
abetting claim to show that the defendant had some extra knowledge about the
primary fraudster in order to create an inference that the defendant knew of
the fraud and passed it through the review process anyways.” But here, “no
extra knowledge is required. That is because the advertisements are facially
ridiculous.” [This seems like it will create a bit of a problem on the back end
of proving classic fraud—where is the reasonable reliance?]

Thus, an ad showing “Savita Subramanian, one of Wall
Street’s most respected market observers, purporting to offer stock tips in a
WhatsApp group,” not through her employer Bank of America but promoting
something called “AI Investment.” “She” touted daily potential returns that
were roughly three to four times the average annual return of U.S. equity
markets, all for free. “Even a cursory look would warrant suspicion that the ad
is fraudulent….  If Plaintiffs succeed in
convincing a jury that this ad (and others that are equally preposterous)
passed Meta’s ad review process, the jury would be entitled to infer that Meta
had actual knowledge of the fraud at the time the ads went out to its users.”

Meta made the obvious point that its ad review is not human
review, and that automated systems don’t have the intuitive knowledge that
allows this conclusion from a “cursory look.” The court found that response
“confounding.” “It was Meta’s decision to use technological review tools to
screen ads, and it does not now get to claim it had no idea what was going on
because it tasked some software program with doing the first pass.” But … Meta
did have no idea what was going on, in the sense of having specific knowledge.
This really is a decision to allow general knowledge to count for liability; it
penalizes Meta for having automated review instead of no review. Given that
human review at Meta scale is … let’s say unlikely … then allowing this
generalized knowledge to count is another blow against large online services
generally.

The court also found that it was plausible that Meta
acquired knowledge that it was aiding and abetting a fraud “well before the ad
passed through a review system.” “At the moment a scammer asked Advantage+
Creative to generate an ad using a celebrity, a secret chat room, and the
promise of unfathomable riches, there is at least a fact question on whether
Meta acquired knowledge that it was aiding and abetting a fraud.” After all,
“even routine operations may constitute substantial participation if done with
knowledge.”

Breach of contract: Meta didn’t impose a binding contractual
obligation on itself to do anything, only a duty on its users not to pollute
Meta’s platforms with scam investment ads. For similar reasons, alternative
claims for promissory estoppel and for breach of the covenant of good faith and
fair dealing failed.

But negligence survived for the reasons above.

California’s Unruh Act provides that all individuals,
regardless of race or national origin, shall be “entitled to the full and equal
accommodations, advantages, facilities, privileges, or services in all business
establishments of every kind whatsoever.” Plaintiffs alleged that Meta’s
advertising tools targeted ads featuring celebrities and investors that shared
their race or national origin to make it more likely that they’d engage with
the ad and succumb to the scam. “In general, a person suffers discrimination
under the [Unruh] Act when the person presents himself or herself to a business
with an intent to use its services but encounters an exclusionary policy or
practice that prevents him or her from using those services.” Targeting is not
exclusion, so there was no violation.

Unjust enrichment also survived.

from Blogger https://tushnet.blogspot.com/2026/04/metas-ai-assistance-to-advertisers.html

Posted in Uncategorized | Tagged , | Leave a comment

CA6 interprets literal falsity narrowly but says materiality implements the standing requirement, yay

Victory Global, LLC v. Fresh Bourbon, LLC, — F.4th —-,
2026 WL 836221, No. 25-5173 (6th Cir. Mar. 26, 2026)

Lower
court decision discussed here.

Victory Global, d/b/a Brough Brothers claims to have become
the “first” African American-owned company to distill bourbon when it opened
its physical distillery in 2020. But Fresh Bourbon counters that it was the
“first” because its owners physically distilled their brand at another
company’s distillery two years earlier. Brough Brothers sued for Lanham Act
false advertising, but failed to identify any unambiguously false statements or
evidence of deception. The court of appeals affirmed the grant of summary
judgment to Fresh Bourbon.

Brough Brothers sold their its batch of bourbon under the
Brough Brothers label in 2020. The bottles truthfully disclosed that they were
distilled in Indiana. On New Year’s Eve in 2020, they distilled their first
bourbon in Kentucky.

Fresh Bourbon distilled using another distillery’s space starting
in 2018; eventually, Fresh Bourbon’s employees knew what they were doing and
got “free reign” [sigh] of the Hartfield distillery. It first sold its bourbon made
at Hartfield in 2020, using Hartfield’s federal license to sell to
distributors. The label stated: “Distilled and Bottled by Buchanan Griggs Inc.
Paris, Kentucky For Fresh Bourbon Distilling Company[.]” Fresh Bourbon owned
the recipe for this bourbon, and Hartfield agreed not to make it for others.
Eventually, Fresh Bourbon opened its own distillery and distilled its first
batch either in late 2022 or in early 2023.

“Given that Brough Brothers and Fresh Bourbon developed side
by side, various sources have made different claims about who came first.”

“If a defendant makes a literally false statement, the
defendant can identify no possible framing in which one could consider the
statement true.” [This is an overstatement—we can always imagine secret
definitions that make a statement true.]  By contrast, a misleading statement “requires
a reader to engage in some mental processing to determine its truth or falsity.”
[Also wrong: the whole point of falsity/misleadingness is that the reader does not
know the truth by way of the statement. A misleading statement requires some inference
that leads the reader to a false conclusion; the mental processing is the
process of determining what the statement is saying.] “If, for
example, an ambiguous statement is true under one interpretation but false
under another, the statement qualifies as potentially misleading (not literally
false). The same rule covers a technically true statement that lacks important
details.”

The court noted that other circuits have split over whether
the false/misleading line matters to materiality. Now here’s a line I like a
lot: Materiality “implements the statutory causation requirement because a
business is not ‘likely to be damaged’ from a claim that will not affect a
consumer’s decision on which product to buy.” The court declined to weigh in on
the split here (correctly recognizing that the Fifth Circuit had mistakenly cited
it as already having resolved the issue; indeed, the Fifth Circuit cited its
misunderstanding of other courts’ holdings as the reason it adopted a
separate-evidence-for-materiality requirement; the split emerged from a game of
Telephone).

Anyway, Brough Brothers bet it all on literal falsity. But
none of the categories of challenged statements met the “high” bar for literal
falsity.

First: The first to African Americans to “distill,”
“produce,” or “develop” Kentucky bourbon since the Civil War. For example,
Fresh Bourbon’s profile on X called the company’s bourbon the “first …
developed grain to glass by African Americans in the state of Kentucky.”

Brough Brothers’ expert conceded that it was “impossible to
verify” whether other African American distilleries existed before these two
companies because of the history of ignoring Black history. “At least with
respect to other bourbon makers, then, Fresh Bourbon’s statements are not ‘verifiable’
as false on this record.” So the alleged falsity was the message that Fresh
Bourbon made bourbon at its Lexington distillery before Brough Brothers made
bourbon at its Louisville distillery, when the truth was that Brough Brothers
obtained its distilling licenses and made its first batch of bourbon at its own
distillery in December 2020 before Fresh Bourbon completed the same tasks years
later. “If, then, the challenged statements unambiguously suggested that Fresh
Bourbon opened its physical location before Brough Brothers, they would likely
be literally false.” 

But there was another “reasonable” reading [applying the
correct standard rather than the “any reading” standard]: “that Fresh Bourbon’s
agents made its Kentucky bourbon first—no matter the physical distillery at
which it did so.” And that was true. Fresh Bourbon’s founders participated in
the distilling process at the Hartfield distillery starting in 2018. During
this time, Brough Brothers sourced their bourbon from Indiana and did not help
this producer in the distilling process. Under these circumstances, there was
ambiguity.

Brough Brothers argued that a party does not “distill,”
“produce,” or “develop” bourbon unless the party obtains licenses to open a
distillery.

But this technical claim has no
place in the “literally false” calculus—which requires a “bald-faced” lie. Fresh
Bourbon’s use of these verbs does not meet that high standard. In ordinary
language, one would naturally say that a party distilled or produced bourbon
when the party put the raw materials into a still and took the other steps
necessary to create the alcoholic beverage at the end.… These verbs also would
remain accurate even if the party lacked a license.

The legality claim thus “conflicts with the ordinary
understanding of the words.” And the facts showed that Fresh Bourbon’s team did
more than buy bourbon on Hartfield’s license; they physically participated in
the distilling.

Second: “[C]onsidered to be the first black-owned distillery
in Kentucky.” This phrase came from the Kentucky Senate’s resolution praising
Fresh Bourbon in February 2020, to which Fresh Bourbon’s website links. Brough
Brothers argued that it opened its Louisville distillery before Fresh Bourbon
opened its Lexington one, making this literally false.

But there was no evidence that Fresh Bourbon itself ever
claimed to have opened the first African American-owned distillery in
Kentucky. That the Kentucky Senate “considered” it to be the first, even if misleading,
wasn’t literally false. Also, “distillery” could mean different things in
different contexts. Although both dictionaries and Kentucky law define the term
as meaning a place where distilled spirits are made, “consumers do not
necessarily flip open a dictionary or check statutes when evaluating products.”
And Fresh Bourbon introduced evidence that companies often call themselves a
“distillery” even when they are “having a spirit bottled for” them by others. Brough
Brothers itself registered the name “Brough Brothers Distillery” in 2018—years
before it opened its physical location. The resolution itself suggested that
this was how the Kentucky Senate used the term, because it stated elsewhere that
Fresh Bourbon had “announced that they plan to build” a physical distillery in
Lexington. “[I]t would have made little sense for the resolution to refer to
Fresh Bourbon’s (unconstructed) venue as the first.” Under the understanding of
“distillery” that means a company that sells bourbon, Fresh Bourbon sold
Kentucky-made bourbon while Brough Brothers still sold Indiana-made bourbon, so
that was true.

Brough Brothers argued that Fresh Bourbon drafted the resolution
and was thus responsible for it, but the Senate didn’t use the language that
they drafted, which didn’t include the challenged statement. Thus the court
didn’t resolve the question of whether a state Senate resolution could be
attributed to a private party for Lanham Act purposes.

Likewise with other claims; the Senate resolution also said
that Fresh Bourbon “produces bourbon in the state of Kentucky with an African
American Master Distiller, the first in Kentucky since slavery[.]” Brough
Brothers argued that this statement was literally false because the putative
master distiller lacked the qualifications: “20+ years of experience operating
a distillery,” according to its expert. The putative master distiller “worked
full time at a bank and merely had an interest in bourbon as a hobby before he
took the job with Fresh Bourbon.” But the record showed that whether a producer
qualifies as a “master distiller” was opinion not fact; as one witness said,
the term is “more of a symbol” that some distillers coined in their marketing
to become “rock stars with the bourbon people.” He testified that there is “no
set experience level” or “no set anything” for that matter; the claim that a
master distiller must have 20 years’ experience would disqualify Brough
Brothers’ own master distiller. Brough Brothers’ expert conceded that it
“[b]asically” boils down to “a matter of opinion,” which is fatal to a Lanham
Act claim.

The court also declined to hold that these statements added
up to falsity by necessary implication. Unfortunately casting doubt on whether the
circuit actually recognized the doctrine, it understandably refused to “combine
statements from different sources into one ‘overall marketing scheme.’” Context
is vital, but “we have never treated every advertisement that a business has
ever made as the relevant ‘context.’” Even considered together, however, the
challenged statements were still ambiguous.

from Blogger https://tushnet.blogspot.com/2026/04/ca6-interprets-literal-falsity-narrowly.html

Posted in Uncategorized | Tagged | Leave a comment